2Jordan J.Mechanism of action of interferon and ribavirin in treatment of hepatitis C[J].Nature 2005,436(8):967
3Zeuzem S,Feinman S V,Rasenack J,et al.Peginterferon alfa-2a in patients with chronic hepatitis C[J].N Engl J Med,2000,343(23):1666
4Reddy K R.Controlled-release,pegylated,liposomal formulations:new mechanisms in the delivery of injectable drugs[J].Ann Pharmacother,2000,34(7):915
5Manns M P,McHutchison J G,Gordon S C,et al.Peginterferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:results of a randomized trial[J].Lancet,2001,358(9286):958
6Xu Z - X, Hoffman J, Patel I, et al .Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEGIFN) and interferon alpha-2a (IFNa-2a) to heathy subjects [J]. Hepatology, 1998, 28: Suppl: 702A.
7Zeuze m S. Clinical implications of hepatitis C viral kinetics [ J ]. J Hepatol, 1999, 31 (Suppl): 61-64.
8Monkarsh SP, Ma Y, Aglione A, et al . Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal Biochem, 1997: 247: 434-440.
